USS Investment Management Ltd Purchases New Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

USS Investment Management Ltd purchased a new position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,038 shares of the company's stock, valued at approximately $706,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in Cellebrite DI in the 4th quarter worth about $9,995,000. Teacher Retirement System of Texas bought a new position in Cellebrite DI in the 4th quarter worth about $442,000. New York State Common Retirement Fund increased its stake in Cellebrite DI by 2.6% in the 4th quarter. New York State Common Retirement Fund now owns 189,599 shares of the company's stock worth $4,177,000 after acquiring an additional 4,838 shares during the last quarter. SG Americas Securities LLC increased its stake in Cellebrite DI by 2,244.2% in the 4th quarter. SG Americas Securities LLC now owns 209,529 shares of the company's stock worth $4,616,000 after acquiring an additional 200,591 shares during the last quarter. Finally, Pembroke Management LTD increased its stake in Cellebrite DI by 4.4% in the 4th quarter. Pembroke Management LTD now owns 1,992,432 shares of the company's stock worth $43,893,000 after acquiring an additional 84,087 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on CLBT shares. JPMorgan Chase & Co. cut their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Needham & Company LLC cut their price objective on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Finally, Lake Street Capital upped their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $22.43.

Cellebrite DI Stock Performance

CLBT stock traded down $0.26 during trading on Friday, hitting $16.52. 497,393 shares of the company traded hands, compared to its average volume of 1,456,494. The firm has a market capitalization of $3.96 billion, a PE ratio of -11.95, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 1 year low of $10.25 and a 1 year high of $26.30. The company has a 50-day moving average of $18.73 and a 200-day moving average of $20.13.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The business had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. During the same quarter in the previous year, the firm posted $0.08 earnings per share. Cellebrite DI's quarterly revenue was up 20.0% on a year-over-year basis. Sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.